Pfizer sues Novartis over Vfend (Voriconazole) antifungal patents

Pfizer Inc. has sued Novartis' Sandoz unit, claiming infringement of its U.S. patents related to the antifungal treatment Vfend which contains Voriconazole as active agent.

Pfizer alleges that Sandoz is seeking permission from the U.S. Food and Drug Administration to sell a generic version of Vfend before the expiration of two patents issued in 1994 and 2003, respectively.

Pfizer in its complaint filed with the U.S. district court in Wilmington, Delaware has sought the court’s order to block Sandoz from selling any version of Vfend before the patents expire.
(Source: http://www.itagbs.com/weekly_news.html)